News
BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib at the European Society for Medical Oncology (ESMO) 2019 Congress
September 27, 2019
Bergen, Norway, 27 September 2019 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read MoreBerGenBio to Present at H.C. Wainwright 21st Annual Global Life Sciences Conference
September 10, 2019
Bergen, Norway, September 10 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib in Non-Small Cell Lung Cancer at 2019 World Conference on Lung Cancer
September 8, 2019
Bergen, Norway, 8 September 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read More
BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF 2019
August 19, 2019
Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo…
Read More
BerGenBio presents preliminary Phase II clinical data at EHA 24: bemcentinib in combination with low dose chemotherapy yields durable responses in AML patients unfit for intensive chemotherapy
June 14, 2019
Two posters to be presented at the 2019 annual congress of the European Hematology Association…
Read More
BerGenBio presents new Phase II clinical data that bemcentinib in combination with low dose chemotherapy improves efficacy and duration of survival in elderly AML patients at ASCO 2019
June 3, 2019
Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy n elderly AML patients…
Read More
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159